Description
Description: Kadcyla is an injectable medication manufactured by Roche Holding AG. Each injection vial contains 160 milligrams of Trastuzumab Emtansine, a targeted therapy used in the treatment of HER2-positive breast cancer.
Indications: Kadcyla (Trastuzumab Emtansine) is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who have previously received treatment with trastuzumab and a taxane chemotherapy. It is specifically designed to target cancer cells that overexpress the HER2 protein.
Mechanism of Action: Trastuzumab Emtansine is a conjugate of Trastuzumab, a monoclonal antibody that targets the HER2 protein, and emtansine, a microtubule inhibitor. It works by binding to the HER2 protein on the surface of cancer cells, delivering emtansine directly into the cancer cells, where it disrupts microtubule function and inhibits cell division and growth.
Administration: Kadcyla is administered intravenously under the supervision of a healthcare professional experienced in the use of chemotherapy medications. The dosage and frequency of administration may vary depending on factors such as the patient’s overall health status and response to treatment.
Dosage and Treatment Plan: The dosage of Kadcyla (Trastuzumab Emtansine) will be determined by a healthcare provider based on individual patient factors, including body weight and tolerability. Treatment typically consists of a specified dosage administered every three weeks until disease progression or unacceptable toxicity occurs.
Side Effects: Common side effects associated with Kadcyla may include fatigue, nausea, vomiting, diarrhea, headache, muscle pain, and hair loss. More serious side effects may include cardiotoxicity, liver toxicity, infusion-related reactions, thrombocytopenia, and peripheral neuropathy.
Precautions:
- Kadcyla should be used with caution in patients with pre-existing cardiac or hepatic impairment, as well as those with a history of hypersensitivity to Trastuzumab or emtansine.
- It is important for healthcare providers to monitor patients closely for signs of cardiac toxicity, including decreased left ventricular ejection fraction.
- Pregnant or breastfeeding women should avoid using Kadcyla, as it may harm the fetus or infant.
Consultation with a Healthcare Provider: Before starting treatment with Kadcyla (Trastuzumab Emtansine), individuals should consult with a healthcare provider or qualified oncologist. They can provide guidance on proper usage, dosage, and potential risks associated with the medication. Regular monitoring and evaluation are essential to ensure safety and efficacy during treatment.
Reviews
There are no reviews yet.